# Integrating multi-dimensional data to reveal the mechanisms and molecular targets of baikening granules for treatment of pediatric influenza

## TL;DR

This study explores how Baikening granules treat pediatric influenza by identifying key molecular targets and pathways involved in the process.

## Contribution

The study identifies novel molecular targets and active compounds in Baikening granules for treating pediatric influenza using multi-omics and computational methods.

## Key findings

- Baikening granules may target core genes like PPARG and MMP2 to treat pediatric influenza.
- Two hub genes, OTOF and IFI27, show potential as biomarkers for BKN-related influenza treatment.
- Molecular docking and dynamics confirm stable binding between BKN components and hub genes.

## Abstract

Children are the main group affected by the influenza virus, posing challenges to their health. The high risk of viral variability, drug resistance, and drug development leads to a scarcity of therapeutic drugs. Baikening (BKN) granules are a marketed traditional Chinese medicine used to treat children’s lung heat, asthma, whooping cough, etc. Therefore, exploring the potential mechanisms of BKN in treating pediatric influenza is of great significance for discovering new drugs.

Through the database, we obtained differentially expressed genes (DEGs) between pediatric influenza and healthy samples, identified the components of BKN, and collected the targets. Target networks were built with the purpose of screening both targets and key components. Pathway and function enrichment were conducted on the relevant targets of BKN for treating pediatric influenza. BKN-related hub genes for influenza were discovered through DEGs, weighted gene co-expression network analysis (WGCNA), BKN-cluster WGCNA, and machine learning model. The accuracy of prediction efficiency and the value of BKN-related hub gene were validated through analysis of external datasets and receiver operating characteristics. Ultimately, simulations using molecular docking and molecular dynamics were used to forecast how active components will bind to hub genes.

A total of 20 candidate active compounds, 58 potential targets, and 3,819 DEGs were identified. The target network screened the top 10 key components and 6 core targets (PPARG, MMP2, GSK3B, PARP1, CCNA2, and IGF1). Potential target enrichment analysis indicated that BKN may be involved in AMPK signaling pathway, PI3K Akt signaling pathway, etc., to combat pediatric influenza. Subsequently, two hub genes (OTOF, IFI27) were obtained through WGCNA, BKN-cluster WGCNA, and machine learning models as potential biomarkers for BKN-related pediatric influenza. Two hub genes were found to have primary diagnostic value based on ROC curve analysis. Molecular docking confirmed the binding between BKN and hub gene. Molecular dynamics further revealed the stable binding between Peimisine and hub genes.

BKN may alleviate pediatric influenza via key components targeting core targets (PPARG, MMP2, GSK3B, PARP1, CCNA2, and IGF1) and hub genes (OTOF, IFI27), with the involvement of feature genes-related pathways. These results have potential consequences for future research and clinical practice.